A recently approved targeted chemotherapy drug can significantly extend the lives of advanced breast cancer patients who have ...

EXCLUSIVE: Loose Women star Nadia Sawalha has shared her heartbreak as she continues campaigning for the life-extending drug to be made available in England, Wales and Northern Ireland.

Loose Women panellist Nadia Sawalha has been campaigning for the life-changing drug Enhertu to be made available in Wales, ...

Tributes have been paid to "inspirational" Darlington grandmother and campaigner Heather Sawyer who has sadly passed away after a ...

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that you might not know about.

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...